Table 1.
Patient Demographics and Clinical Characteristics By Plasma:RBC ratio at 24 hours
| Characteristic | 0 N=252 |
0.1-0.4 N=172 |
0.5-0.9 N=204 |
1.0+ N=81 |
Total N=709 |
p-value |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age | 66.5 (54.2, 76.9) | 65.4 (55.6, 76.3) | 63.3 (50.9, 74.4) | 61.9 (47.1, 71.9) | 64.6 (52.8, 75.8) | 0.03 † |
| Male Sex | 143 (56.7%) | 104 (60.5%) | 125 (61.3%) | 42 (51.9%) | 414 (58.4%) | 0.44 ‡ |
| Charlson Score | 6 (4, 9) | 6 (4, 9) | 6.0 (3.5, 8.0) | 5 (2, 8) | 6 (4, 9) | 0.07 † |
| Massive Transfusion + | 16 (6.3%) | 52 (30.2%) | 70 (34.3%) | 11 (13.6%) | 149 (21.0%) | <0.001 ‡ |
| Patient Location | 0.02 ‡ | |||||
| ICU | 208 (82.5%) | 146 (84.9%) | 164 (80.4%) | 59 (72.8%) | 577 (81.4%) | |
| Emergency Room | 23 (9.1%) | 17 (9.9%) | 29 (14.2%) | 19 (23.5%) | 88 (12.4%) | |
| Floor | 21 (8.3%) | 9 (5.2%) | 11 (5.4%) | 3 (3.7%) | 44 (6.2%) | |
| Anatomical site | 0.76 ‡ | |||||
| Gastrointestinal | 95 (37.7%) | 59 (34.3%) | 73 (35.8%) | 33 (40.7%) | 260 (36.7%) | |
| Intraabdominal | 42 (16.7%) | 36 (20.9%) | 36 (17.6%) | 23 (28.4%) | 137 (19.3%) | |
| Thoracic | 31 (12.3%) | 21 (12.2%) | 28 (13.7%) | 8 (9.9%) | 88 (12.4%) | |
| Hematologic | 15 (6.0%) | 9 (5.2%) | 11 (5.4%) | 5 (6.2%) | 40 (5.6%) | |
| Multifactorial | 9 (3.6%) | 8 (4.7%) | 13 (6.4%) | 1 (1.2%) | 31 (4.4%) | |
| Retroperitoneal | 12 (4.8%) | 9 (5.2%) | 9 (4.4%) | 0 (0.0%) | 30 (4.2%) | |
| Vascular | 11 (4.4%) | 9 (5.2%) | 7 (3.4%) | 3 (3.7%) | 30 (4.2%) | |
| Other | 16 (6.3%) | 11 (6.4%) | 13 (6.4%) | 6 (7.4%) | 46 (6.5%) | |
| Unknown | 21 (8.3%) | 10 (5.8%) | 14 (6.9%) | 2 (2.5%) | 47 (6.6%) | |
| Medical or Post-Surgical | 0.34 ‡ | |||||
| Medical | 181 (71.8%) | 126 (73.3%) | 140 (68.6%) | 51 (63.0%) | 498 (70.2%) | |
| Post-Surgical | 71 (28.2%) | 46 (26.7%) | 64 (31.4%) | 30 (37.0%) | 211 (29.8%) | |
| PLT:RBC Ratio | <0.001 ‡ | |||||
| 0 | 202 (80.2%) | 81 (47.1%) | 68 (33.3%) | 33 (40.7%) | 384 (54.2%) | |
| 0.1-0.9 | 6 (2.4%) | 37 (21.5%) | 45 (22.1%) | 12 (14.8%) | 100 (14.1%) | |
| 1.0-2.0 | 31 (12.3%) | 46 (26.7%) | 69 (33.8%) | 26 (32.1%) | 172 (24.3%) | |
| 2.1+ | 13 (5.2%) | 8 (4.7%) | 22 (10.8%) | 10 (12.3%) | 53 (7.5%) | |
| RBC Units | 4 (3, 5) | 6 (5, 9) | 6.5 (4.0, 10.0) | 4 (3, 7) | 5 (4, 7) | <0.001 † |
| Laboratory values before CAT+ | ||||||
| Hemoglobin,g/dL | 7.1 (6.0, 8.8) | 7.3 (5.7, 8.7) | 7.7 (6.3, 9.1) | 7.4 (6.5, 10.3) | 7.3 (6.0, 9.0) | 0.07 † |
| Platelet Count, x109/L | 164 (100, 258) | 146 (90, 216) | 135 (81, 195) | 139.5 (80.0, 209.0) | 148 (89, 225) | 0.03 † |
| INR | 1.2 (1.1, 1.4) | 1.4 (1.2, 1.8) | 1.4 (1.2, 2.0) | 1.7 (1.3, 2.4) | 1.3 (1.1, 1.8) | <0.001 † |
| Medications before CAT+ | ||||||
| Heparin | 29 (11.5%) | 17 (9.9%) | 15 (7.4%) | 8 (9.9%) | 69 (9.7%) | 0.53 ‡ |
| Direct thrombin inhibitor | 2 (0.8%) | 2 (1.2%) | 1 (0.5%) | 0 (0.0%) | 5 (0.7%) | 0.74 § |
| Warfarin | 42 (16.7%) | 25 (14.5%) | 29 (14.2%) | 23 (28.4%) | 119 (16.8%) | 0.02 ‡ |
| Aspirin | 126 (50.0%) | 75 (43.6%) | 83 (40.7%) | 24 (29.6%) | 308 (43.4%) | 0.01 ‡ |
| LMW Heparin | 25 (9.9%) | 10 (5.8%) | 11 (5.4%) | 6 (7.4%) | 52 (7.3%) | 0.24 ‡ |
| Clopidogrel within 7 Days | 30 (11.9%) | 13 (7.6%) | 16 (7.8%) | 3 (3.7%) | 62 (8.7%) | 0.10 § |
| Factor Xa | 5 (2.0%) | 1 (0.6%) | 2 (1.0%) | 1 (1.2%) | 9 (1.3%) | 0.61 § |
| Hemostatic medications | ||||||
| Vitamin K | 12 (4.8%) | 28 (16.3%) | 25 (12.3%) | 20 (24.7%) | 85 (12.0%) | <0.001 ‡ |
| Antifibrinolytic agents | 3 (1.2%) | 7 (4.1%) | 9 (4.4%) | 8 (9.9%) | 27 (3.8%) | 0.004 § |
| PCCs | 2 (0.8%) | 5 (2.9%) | 3 (1.5%) | 1 (1.2%) | 11 (1.6%) | 0.38 § |
Numbers indicate N (%) unless otherwise noted.
†
Kruskal-Wallis
‡
Chi-square
§
Fisher exact
Massive transfusion + defined as administration of ≥10 units of RBCs within 24 hours.
Abbreviations: RBC, red blood cells; PLT, platelets; INR, international normalized ratio; LMW, low molecular weight heparin; CAT, critical administration threshold; PCC, prothrombin complex concentrate.